Status:
COMPLETED
Neurobiological and Neurocognitive Disturbances in First-episode Schizophrenia
Lead Sponsor:
Birte Glenthoj
Collaborating Sponsors:
Rigshospitalet, Denmark
Copenhagen University Hospital, Hvidovre
Conditions:
Schizophrenia
Eligibility:
All Genders
18-45 years
Phase:
NA
Brief Summary
We want to relate disturbances in first-episode schizophrenic patients in serotonin 5-HT2A receptors, brain structure, brain function, and information processing to each other and to psychopathology. ...
Detailed Description
Patients and matched healthy controls are examined at baseline and again after the patients have been treated for 6 months with a combined 5-HT2A- and dopamine D2- receptor blocker. We have chosen the...
Eligibility Criteria
Inclusion
- First-episode schizophrenia. The controls are matched for age, gender and parental socioeconomic status
Exclusion
- Previous antipsychotic treatment, mental retardation, organic brain damage, and for the controls a psychiatric diagnosis or first-degree relatives with a psychiatric diagnosis
Key Trial Info
Start Date :
April 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2008
Estimated Enrollment :
46 Patients enrolled
Trial Details
Trial ID
NCT00207064
Start Date
April 1 2004
End Date
September 1 2008
Last Update
September 19 2011
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Neurobiology Research Unit, Rigshospitalet
Copenhagen, Denmark, DK-2100
2
Center for Neuropsychiatric Schizophrenia Research, University of Copenhagen, Psychiatric Center Glostrup
Glostrup Municipality, Denmark, DK-2600
3
Danish Research Center for Magnetic Resonance Imaging, Hvidovre Hospital
Hvidovre, Denmark, DK-2650